Correlation Between OBI Pharma and GeneReach Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both OBI Pharma and GeneReach Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining OBI Pharma and GeneReach Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between OBI Pharma and GeneReach Biotechnology, you can compare the effects of market volatilities on OBI Pharma and GeneReach Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in OBI Pharma with a short position of GeneReach Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of OBI Pharma and GeneReach Biotechnology.

Diversification Opportunities for OBI Pharma and GeneReach Biotechnology

0.43
  Correlation Coefficient

Very weak diversification

The 3 months correlation between OBI and GeneReach is 0.43. Overlapping area represents the amount of risk that can be diversified away by holding OBI Pharma and GeneReach Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on GeneReach Biotechnology and OBI Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on OBI Pharma are associated (or correlated) with GeneReach Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of GeneReach Biotechnology has no effect on the direction of OBI Pharma i.e., OBI Pharma and GeneReach Biotechnology go up and down completely randomly.

Pair Corralation between OBI Pharma and GeneReach Biotechnology

Assuming the 90 days trading horizon OBI Pharma is expected to under-perform the GeneReach Biotechnology. But the stock apears to be less risky and, when comparing its historical volatility, OBI Pharma is 1.05 times less risky than GeneReach Biotechnology. The stock trades about -0.04 of its potential returns per unit of risk. The GeneReach Biotechnology is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  2,705  in GeneReach Biotechnology on December 4, 2024 and sell it today you would lose (5.00) from holding GeneReach Biotechnology or give up 0.18% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

OBI Pharma  vs.  GeneReach Biotechnology

 Performance 
       Timeline  
OBI Pharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days OBI Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.
GeneReach Biotechnology 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days GeneReach Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

OBI Pharma and GeneReach Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with OBI Pharma and GeneReach Biotechnology

The main advantage of trading using opposite OBI Pharma and GeneReach Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if OBI Pharma position performs unexpectedly, GeneReach Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GeneReach Biotechnology will offset losses from the drop in GeneReach Biotechnology's long position.
The idea behind OBI Pharma and GeneReach Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

Bonds Directory
Find actively traded corporate debentures issued by US companies
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Commodity Directory
Find actively traded commodities issued by global exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories